Network-based transcriptomics applied to validate candidate biomarkers and explore biological relationships in AML.
Mavatar, global specialist in data-driven precision medicine solutions, today announces a research collaboration with the group of Bruno Paiva, one of Europe's most cited researchers in hematologic neoplasms, Director of Flow Cytometry at Clínica Universidad de Navarra and Principal Investigator of the Translational Immunomics in Hematological Neoplasms Research Group at Cima Universidad de Navarra, Spain.
The collaboration applies Mavatar Discovery to support the group's research program in acute myeloid leukemia (AML). Specifically, the work explores whether differentially expressed genes identified in clinical cohorts can be confirmed and contextualized in large-scale transcriptomic datasets - and how network-based analysis can reveal the biological relationships between candidate markers and other genes relevant in AML. This network layer adds a further dimension to the validation of candidate biomarkers, strengthening confidence in their biological role.
The current collaboration focuses on AML, with both parties expressing interest in extending the work into multiple myeloma - a field in which Bruno Paiva is internationally recognized as one of the leading researchers.
"Mavatar Discovery changes how we approach the early stages of a research question. Instead of relying solely on what we can generate in our own cohort, we can immediately explore how our findings relate to the broader biological landscape - across diseases, tissues and datasets. For a research group working across multiple hematologic malignancies, that kind of systems-level context is genuinely valuable," says Bruno Paiva, PhD, Principal Investigator, Clínica Universidad de Navarra.
Danuta Gawel, Chief R&D Officer at Mavatar, welcomes the collaboration as part of a broader academic strategy:
"Some of the most important biological questions are sitting in data that already exists. We want to give researchers the tools to find those answers, without needing a bioinformatics team to do it. We are delighted to welcome Bruno Paiva and his team to our growing network of university and industry collaborators," says Danuta Gawel, Chief R&D Officer at Mavatar.
The collaboration with the Clínica Universidad de Navarra joins an expanding portfolio of academic and industry partnerships. On the academic side, Mavatar works with Professor Tomas Deierborg at Lund University, Associate Professor Henrietta Nielsen at Stockholm University, and Associate Professor Olav Michael Andersen at Aarhus University. In industry, Mavatar works with a range of pharmaceutical and biopharmaceutical companies applying Mavatar Discovery to accelerate drug discovery and target validation - among them Sobi, the global rare disease biopharmaceutical company.
About Clínica Universidad de Navarra:
With 4,000 full-time professionals across its Pamplona and Madrid campuses, Clínica Universidad de Navarra is an academic hospital and a leading institution in personalized medicine in Spain. Recognized for its research and teaching activity, the prestige of its professionals, and its track record in the diagnosis and treatment of highly complex diseases, Clínica Universidad de Navarra is a high-resolution hospital, offering rapid diagnosis thanks to its multidisciplinary approach and investment in cutting-edge technology. It provides care in 46 medical and surgical specialties.